|
|
|
In March 2007, the FDA issued a black-box warning for erythropoiesis-stimulating agents. It is recommended that the lowest possible dose be used to help patients avoid blood transfusions. Studies have shown increased mortality and/or a tumor progression in patients with cancer receiving an erythropoiesis-stimulating agent.
For more information, please review the FDA Fact Sheet available
online at:
http://www.fda.gov/cder/drug/infopage/RHE/default.htm
|
|
|
|
|
|
|
Howard L. Corwin, MD
We invite you to join Howard L. Corwin, MD, Medical Director of the Intensive Care Unit at the Dartmouth-Hitchcock Medical Center, Lebanon, NH, to discuss the risks and benefits associated with RBC transfusion in critically ill patients. He reviews transfusion strategies in the critically ill and alternatives to RBC transfusion.
 To take this
course choose your format at the bottom of this page. |
|
Key Words: Exploring Alternatives to Blood Transfusion |
 |
 |
Supported by an educational grant from:
 | |
|
| |
| | | [Top] |
| OVERVIEW |
|
| Almost half of all patients admitted to intensive care units (ICUs) in the United States receive red blood cell (RBC) transfusions. However, RBC transfusion decisions are often made without a complete understanding of the related risks and benefits. The issues surrounding RBC transfusion are particularly important in the critically ill. |
| | | [Top] |
| OBJECTIVES |
|
| Upon completion of this course, you should be able to: |
-
Name the risks and benefits of red blood cell transfusion
-
Describe the etiology of the anemia in critical illness
-
Identify alternatives to red blood cell transfusion for treating anemia in critically ill patients
|
| | | [Top] |
| TARGET AUDIENCE |
|
| This CME activity is designed for critical care physicians, critical care nurses, and other healthcare providers who treat patients with risk factors for anemia. |
| | | [Top] |
| FACULTY |
| |
|
|
 |
| Howard L. Corwin, MD
[BioSketch]
|
| Medical Director,
Dartmouth-Hitchcock Medical Center ICU,
Lebanon, NH |
| Disclosure: Consultant: Ortho Biotech, Johnson & Johnson, ESP
Pharma; Research: Ortho Biotech, Johnson & Johnson |
|
|
|
| | | [Top] |
|
|
| ACCREDITATION STATEMENT |
|
| Continuing Medical Education for Physicians |
 |
| Accreditation Statement |
| MEBN is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
| |
| CME Credits |
| MEBN designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| |
| FDA Disclosure Statement |
| The contents of some CME activities may contain discussions of non-approved or off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. |
| |
| Accreditation Period |
Original release date: March 23, 2006
Reviewed and Renewed: March 23, 2008
Expiration Date: March 23, 2009 |
| |
| Any questions regarding the accreditation of this CME activity should be directed to MEBN. (accreditation@mebn.net) | Continuing Education for Nurses
MEBN is an approved provider of continuing nursing education by the New Hampshire Nurses’ Association Commission on Continuing Education, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. MEBN recognizes that the accredited status refers only to our continuing nursing education activities and does not imply that the ANCC Commission on Accreditation approves or endorses these commercial products.
Contact Hours
MEBN designates this continuing education activity for up to 1 contact hour(s) of nursing continuing education credit.
Accreditation Period
Original release date: March 23, 2006
Reviewed and Renewed: March 23, 2008
Expiration Date: March 23, 2009 |
| | | [Top] |
| DISCLAIMER |
|
|
Disclaimer
This continuing education program may
contain discussion of published and/or investigational uses of agents or
products that are not approved by the Food and Drug Administration (FDA). The
authors, sponsors or publishers do not recommend the use of any agent or product
outside of the official labeled indications. Please refer to the official
prescribing information for each agent or product for discussion of approved
indications, contraindications, and written warnings.
Any procedures, medications, or other courses of diagnosis or
treatment discussed or suggested in this course should not be used by clinicians
without evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product information,
and comparison with recommendations of other authorities.
The authors, contributors, and editorial staff have made
every effort to contact holders of copyright to obtain permission to reproduce
copyright material. However, if any permissions have been inadvertently
overlooked, MEBN will be pleased to make the necessary and reasonable
arrangements. |
| | | [Top] |
| How to Take This Course |
|
|
Choose Your Format To Begin Course:
|
| |
|
| |
| | | [Top] |
| SUPPORTERS |
|
Supported by an educational grant from:
| |
|
| | | [Top] |
| CERTIFICATE FEES |
|
| CME-TODAY offers FREE continuing medical education (CME) credits to recipients of the CD-ROM or CME-TODAY journal. Enter the CE Code listed on the CD-ROM or in the journal when prompted. This free offer expires on May 1, 2008. All others will be assessed a $10.00 processing fee. |
| | | [Top] |
|
|
